Application: ICC, IHC
Clonality: Polyclonal
Host: Rabbit
Reactivity: Human
Protein Description: melanoma antigen family C, 2
Gene Name: MAGEC2
Alternative Gene Name: CT10, MAGE-C2, MAGEE1
Isotype: IgG
Interspecies mouse/rat: ENSMUSG00000030742: 42%, ENSRNOG00000025324: 33%
Entrez Gene ID: 51438
Uniprot ID: Q9UBF1
Buffer: 40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative.
Storage Temperature: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Clonality: Polyclonal
Host: Rabbit
Reactivity: Human
Protein Description: melanoma antigen family C, 2
Gene Name: MAGEC2
Alternative Gene Name: CT10, MAGE-C2, MAGEE1
Isotype: IgG
Interspecies mouse/rat: ENSMUSG00000030742: 42%, ENSRNOG00000025324: 33%
Entrez Gene ID: 51438
Uniprot ID: Q9UBF1
Buffer: 40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative.
Storage Temperature: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
| Cognate Antibody/Antigen for Anti MAGEC2 pAb (ATL-HPA062230 w/enhanced validation) | |
| Antigen | PrEST Antigen MAGEC2 (ATL-APrEST86341) |
| Documents & Links for Anti MAGEC2 pAb (ATL-HPA062230 w/enhanced validation) | |
| Datasheet | Anti MAGEC2 pAb (ATL-HPA062230 w/enhanced validation) Datasheet (External Link) |
| Vendor Page | Anti MAGEC2 pAb (ATL-HPA062230 w/enhanced validation) at Atlas |
| Documents & Links for Anti MAGEC2 pAb (ATL-HPA062230 w/enhanced validation) | |
| Datasheet | Anti MAGEC2 pAb (ATL-HPA062230 w/enhanced validation) Datasheet (External Link) |
| Vendor Page | Anti MAGEC2 pAb (ATL-HPA062230 w/enhanced validation) |
| Citations for Anti MAGEC2 pAb (ATL-HPA062230 w/enhanced validation) – 4 Found |
| Profiling cancer testis antigens in non-small-cell lung cancer. JCI Insight. 2016 Jul 7;1(10):e86837. doi: 10.1172/jci.insight.86837. PubMed |
| Engineering Cancer/Testis Antigens With Reversible S-Cationization to Evaluate Antigen Spreading. Front Oncol. 2022 May 4;12:869393. doi: 10.3389/fonc.2022.869393. eCollection 2022. PubMed |
| Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. J Immunother Cancer. 2019 Nov 14;7(1):302. doi: 10.1186/s40425-019-0787-6. PubMed |
| Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients. Oncoimmunology. 2021 Dec 30;11(1):2015113. doi: 10.1080/2162402X.2021.2015113. eCollection 2022. PubMed |